Thomas T, Lafage M H, Alexandre C
Laboratoire de Biologia du Tissu Osseux, Université de Saint Etienne, France.
J Rheumatol. 1995 Nov;22(11):2183-5.
A 68-year-old postmenopausal woman with osteoporosis received intermittent cyclic etidronate therapy (400 mg/day). No concomitant diseases were noted. A baseline transiliac bone biopsy showed a high bone turnover without impairment due to mineralization. After 2 years of treatment, she had increased osteoid volume, and mineralization lag time corresponded to a variant form of osteomalacia called atypical osteomalacia. No clinical consequence was observed. This is the first case report of such a mineralization defect due to 2 year intermittent cyclic etidronate therapy.
一名68岁的绝经后骨质疏松女性接受了间歇性环磷腺苷疗法（400毫克/天）。未发现合并疾病。基线经髂骨活检显示骨转换率高，且无矿化受损情况。治疗2年后，她的类骨质体积增加，矿化延迟时间符合一种称为非典型骨软化症的骨软化症变体形式。未观察到临床后果。这是首例关于因两年间歇性环磷腺苷疗法导致这种矿化缺陷的病例报告。
